72.19.Z - Other research and experimental development on natural sciences and engineering
21.20.Z - Manufacture of medicines and other pharmaceutical products
62.01.Z - Computer programming activities
62.02.Z - Computer consultancy activities
62.03.Z - Computer facilities management activities
70.22.Z - Business and other management consultancy activities
71.12.Z - Engineering activities and related technical consultancy
71.20.A - Food quality testing and analysis
71.20.B - Other technical testing and analysis
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2018 | 2019 | 2020 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0,7 | -7,3 | 0,3 | 103,8 |
EBITDA | -0,7 | -7,2 | 0,2 | 103,4 |
Short time liabilities | 0,3 | 0,3 | 0,1 | -62,1 |
Equity capital | 8 | 0,7 | 1 | 40,4 |
Operating profit (EBIT) | -0,7 | -7,2 | 0,2 | 103,4 |
Assets | 9,8 | 1 | 1,1 | 8,9 |
Net profit (loss) | -0,7 | -7,3 | 0,3 | 103,8 |
Cash | 3,5 | 0,5 | 0 | -100 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 1,8 | 0,3 | 0,1 | -60,6 |
Working assets | 3,7 | 0,9 | 1 | 10,5 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -8,9 | -1055 | 28,8 | 1083,8 |
Equity capital to total assets | 81,5 | 68,8 | 88,7 | 19,9 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 2.030580997467041 | 2.8858630657196045 | 8.102022171020508 | 5,2 |
Net dept to EBITDA | 5.027491092681885 | 0.07105287909507751 | 0.0001899050548672676 | -0,1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane